Published in Diabetes Care on June 29, 2009
Metformin Pharmacology in Human Cancers: A Proof of Principle Study | NCT03477162
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 3.77
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Obesity and cancer. Oncologist (2010) 3.01
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care (2012) 2.32
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer (2011) 2.30
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2010) 2.26
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Diabetes and lung cancer among postmenopausal women. Diabetes Care (2012) 2.17
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
The critical role of metabolic pathways in aging. Diabetes (2012) 2.12
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 1.76
Diabetes and pancreatic cancer. Mol Carcinog (2012) 1.71
Molecular mechanism of action of metformin: old or new insights? Diabetologia (2013) 1.71
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care (2011) 1.65
Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.60
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila) (2015) 1.49
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle (2011) 1.46
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol (2015) 1.45
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res (2011) 1.43
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care (2012) 1.42
A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem (2009) 1.41
Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. Oncogene (2010) 1.41
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
An energetic tale of AMPK-independent effects of metformin. J Clin Invest (2010) 1.35
Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr (2013) 1.31
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol (2012) 1.29
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One (2013) 1.29
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 1.27
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc (2014) 1.25
Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol (2012) 1.24
Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care (2010) 1.23
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle (2012) 1.22
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis (2013) 1.20
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One (2011) 1.19
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol (2014) 1.11
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget (2012) 1.11
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One (2013) 1.09
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis (2013) 1.08
Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog (2013) 1.07
TOR signaling never gets old: aging, longevity and TORC1 activity. Ageing Res Rev (2010) 1.07
Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol (2013) 1.06
Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas (2013) 1.05
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther (2013) 1.04
Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One (2014) 1.04
Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia (2012) 1.03
Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol (2013) 1.03
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol (2014) 1.03
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) (2015) 1.02
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control (2012) 1.01
Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum (2013) 1.01
Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes (2014) 1.01
Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer (2012) 1.01
Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther (2013) 1.00
Synergistic anti-cancer effect of phenformin and oxamate. PLoS One (2014) 0.99
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci (2015) 0.99
Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol (2013) 0.99
Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (2013) 0.99
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget (2014) 0.99
Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol Med Rep (2012) 0.98
Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Technol Ther (2013) 0.98
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem (2014) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS One (2012) 0.97
Metabolism and breast cancer risk: frontiers in research and practice. J Acad Nutr Diet (2012) 0.96
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem (2002) 6.36
LKB1-dependent signaling pathways. Annu Rev Biochem (2006) 5.91
Deprivation and health in Scotland. Health Bull (Edinb) (1990) 5.21
Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology (2003) 5.09
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia (2006) 3.94
AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol (2007) 3.72
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
Complexity of the TOR signaling network. Trends Cell Biol (2006) 2.21
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med (2005) 1.72
Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev (1998) 1.22
Relation between insulin resistance and breast cancer among Chilean women. Ann Epidemiol (2007) 1.15
The role of the AMP-activated protein kinase in the regulation of energy homeostasis. Novartis Found Symp (2007) 1.12
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 32.97
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet (2008) 16.92
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J (2004) 10.82
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol (2010) 6.91
A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet (2007) 6.87
Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med (2007) 6.85
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet (2008) 5.93
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10
FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat Cell Biol (2004) 4.85
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J (2005) 4.82
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes (2008) 4.57
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Emerging roles of pseudokinases. Trends Cell Biol (2006) 4.48
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care (2003) 4.23
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003) 3.77
Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes (2008) 3.76
Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet (2007) 3.58
The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J (2005) 3.52
PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol (2012) 3.42
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J (2007) 3.11
Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08
Activation of the thiazide-sensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci (2008) 3.07
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J (2010) 2.98
Essential role of PDK1 in regulating cell size and development in mice. EMBO J (2002) 2.93
High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol (2002) 2.92
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem (2002) 2.79
In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J (2003) 2.74
Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J (2008) 2.67
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell (2013) 2.64
Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab (2004) 2.61
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med (2013) 2.37
Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med (2010) 2.36
Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet (2012) 2.34
Protein lipid overlay assay. Sci STKE (2002) 2.33
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci (2008) 2.31
Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A (2009) 2.30
Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet (2006) 2.25
Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase. Biochem J (2002) 2.18
LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett (2003) 2.16
Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J (2003) 2.15
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem J (2006) 2.12
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J (2003) 2.11
Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med (2011) 2.11
The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J (2004) 2.11
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J (2011) 2.10
A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) (2011) 2.07
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) (2013) 2.04
Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes (2007) 2.03
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J (2013) 2.03
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J (2002) 1.93
Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet (2002) 1.89
Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) (2009) 1.87
Kinase drug discovery--what's next in the field? ACS Chem Biol (2012) 1.84
Identifying suspected breast cancer: development and validation of a clinical prediction rule. Br J Gen Pract (2011) 1.84
Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J (2002) 1.80
Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate. FEBS Lett (2005) 1.79
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J (2004) 1.77
Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem (2003) 1.75